Flexible bronchoscopy in molecular biology

Clinics in Chest Medicine

Volumn 22, Issue 2, 2001, Pages 343-353

  Eissa, N Tony ^a   Erzurum, Serpil C ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHUS BIOPSY; CELL DIFFERENTIATION; DIAGNOSTIC VALUE; FIBEROPTIC BRONCHOSCOPY; HUMAN; LUNG DISEASE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW;

EID: 0034960996     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70048-4     Document Type: Article

References (45)

1. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: A double-blind placebo-controlled trial
2. Surfactant suppresses NF-kB activation in human monocytic cells
3. Cystic fibrosis
4. Acute responses of non-human primates to airway delivery, of an adenovirus vector corttaining the human cystic fibrosis transmembrane conductance regulator cDNA
5. Extensive posttranslational deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis
6. Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response
7. Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease
8. Transfer of genes to humans: Early lessons and obstacles to success
9. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication-deficient recombinant adenovirus carrying the cDNA of the normal cystic fibrosis trans-membrane conductance regulator gene in the lung
10. Evaluation of repeat administration of a replication-deficient recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis
11. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
12. Adenoviral vector for gene therapy of inherited and acquired disorders of the lung
13. Opening doors to opportunities. New challenges and new interventions
14. Quantitative assessment of the epithelial and inflammatory cell populations in large airways of normals and individuals with cystic fibrosis
15. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium
16. Decreased superoxide dismutase activity in asthmatic airway epithelium: Correction by inhaled corticosteroid in vivo
17. Inhaled corticosteroids and β-agonists inhibit oxidant production by bronchoalveolar lavage cells from normal volunteers in vivo
18. Evaluation of the respiratory epithelium of normals and individuals with cystic fibrosis for the presence of adenovirus Ela sequences relevant to the use of Ela adenovious vectors for gene therapy for the respiratory manifestations of cystic fibrosis
19. 2
20. A fluorescence video-endoscopy technique for detection of gene transfer and expression
21. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo
22. Interferon-γ and interleukin-4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators
23. Prooxidant iron is present in human pulmonary epithelial clining fluid: Implications for oxidative stress in the lung
24. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
25. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector
26. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
27. Contribution of in vitro culture methods for respiratory epithelial cells to the study of the physiology of the respiratory tract
28. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension
29. Gene therapy for the respiratory manifestations of cystic fibrosis
30. Gene therapy for lung disease
31. IL-6 release and airway administration of human CFTR cDNA adenovirus vector
32. Antioxidant activity in bronchoalveolar lavage fluid from patients with lung cancer
33. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution
34. A bronchoscopic brush biopsy study of large airway mucosal pathology in smokers with chronic bronchitis and in healthy nonsmokers
35. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
36. Accurate quantification of cells recovered by bronchoalveolar lavage
37. Comparison of human lung surface protein profiles from the central and peripheral airways sampled using two regional lavage techniques
38. Localized delivery of particles to a small region of the airways
39. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
40. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages
41. Effect of segmental allergen challenge on airway nitric oxide, eosinophils and cytokines in asthmatics
42. Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis
43. Design of airways and blood vessels considered as branching trees
44. Germ-line gene modification and disease prevention: Some medical and ethical perspectives
45. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis